Ranibizumab and Reduced Fluence PDT for AMD
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ranibizumab
Related studies linked through entity extraction aliases.
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
- Status
- COMPLETED
- Phase
- PHASE2
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE4
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
- Status
- TERMINATED
- Phase
- PHASE3
Lucentis for Inflammatory Macular Edema Trial
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
- Status
- COMPLETED
- Phase
- PHASE2
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE4
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
- Status
- COMPLETED
- Phase
- PHASE3
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
- Status
- COMPLETED
- Phase
- PHASE3
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
- Status
- COMPLETED
- Phase
- PHASE1
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
- Status
- COMPLETED
- Phase
- PHASE1
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
- Status
- UNKNOWN
- Phase
- PHASE3
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
- Status
- COMPLETED
- Phase
- PHASE3
Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
- Status
- COMPLETED
- Phase
- PHASE3
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3